Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

A large new trial falls short of experts’ expectations for combating the neurodegenerative disease. But there could still be ...